KoBioLabs Statistics

Total Valuation

KoBioLabs has a market cap or net worth of KRW 93.21 billion. The enterprise value is 74.89 billion.

Market Cap	93.21B
Enterprise Value	74.89B

Important Dates

The next estimated earnings date is Thursday, August 14, 2025.

Earnings Date	Aug 14, 2025
Ex-Dividend Date	n/a

Share Statistics

KoBioLabs has 19.42 million shares outstanding. The number of shares has increased by 2.42% in one year.

Current Share Class	19.42M
Shares Outstanding	19.42M
Shares Change (YoY)	+2.42%
Shares Change (QoQ)	+0.01%
Owned by Insiders (%)	29.95%
Owned by Institutions (%)	0.29%
Float	13.56M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	1.32
PB Ratio	1.78
P/TBV Ratio	2.70
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-13.11
EV / Sales	1.06
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-16.47

Financial Position

The company has a current ratio of 6.72, with a Debt / Equity ratio of 0.29.

Current Ratio	6.72
Quick Ratio	5.67
Debt / Equity	0.29
Debt / EBITDA	n/a
Debt / FCF	-3.34
Interest Coverage	-9.55

Financial Efficiency

Return on equity (ROE) is -9.56% and return on invested capital (ROIC) is -6.60%.

Return on Equity (ROE)	-9.56%
Return on Assets (ROA)	-4.66%
Return on Invested Capital (ROIC)	-6.60%
Return on Capital Employed (ROCE)	-9.18%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.65
Inventory Turnover	5.15

Taxes

In the past 12 months, KoBioLabs has paid 439.17 million in taxes.

Income Tax	439.17M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -29.31% in the last 52 weeks. The beta is 0.67, so KoBioLabs's price volatility has been lower than the market average.

Beta (5Y)	0.67
52-Week Price Change	-29.31%
50-Day Moving Average	4,966.00
200-Day Moving Average	5,524.95
Relative Strength Index (RSI)	53.19
Average Volume (20 Days)	26,130

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, KoBioLabs had revenue of KRW 70.75 billion and -5.71 billion in losses. Loss per share was -295.84.

Revenue	70.75B
Gross Profit	50.29B
Operating Income	-8.07B
Pretax Income	-4.92B
Net Income	-5.71B
EBITDA	-5.34B
EBIT	-8.07B
Loss Per Share	-295.84

Full Income Statement

Balance Sheet

The company has 50.71 billion in cash and 15.19 billion in debt, giving a net cash position of 35.52 billion or 1,828.96 per share.

Cash & Cash Equivalents	50.71B
Total Debt	15.19B
Net Cash	35.52B
Net Cash Per Share	1,828.96
Equity (Book Value)	52.39B
Book Value Per Share	1,812.47
Working Capital	53.17B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -4.37 billion and capital expenditures -172.58 million, giving a free cash flow of -4.55 billion.

Operating Cash Flow	-4.37B
Capital Expenditures	-172.58M
Free Cash Flow	-4.55B
FCF Per Share	-234.13

Full Cash Flow Statement

Margins

Gross margin is 71.09%, with operating and profit margins of -11.41% and -8.07%.

Gross Margin	71.09%
Operating Margin	-11.41%
Pretax Margin	-6.96%
Profit Margin	-8.07%
EBITDA Margin	-7.55%
EBIT Margin	-11.41%
FCF Margin	n/a

Dividends & Yields

KoBioLabs does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-2.42%
Shareholder Yield	n/a
Earnings Yield	-6.13%
FCF Yield	-4.88%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

KoBioLabs has an Altman Z-Score of 0.31 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.31
Piotroski F-Score	5